Rex Medical, L.P. news
CONSHOHOCKEN, Pa. Mar. 19, 2019 --(BUSINESS WIRE)--Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiveness of the Revolution™ Peripheral Atherectomy System in t
November 7, 2018 — At VIVA 2018, the Vascular Interventional Advances annual conference held November 5–8 in Las Vegas, Nevada, Micah Watts, MD, presented findings from the first-in-human clinical trial of the Large Bore Closer vascular sealing system (Rex Medical).
The trial evaluated 23 patients at a single site and assessed the safety and effectiveness of the Large Bore Closer device in sealing femoral arterial access sites at the completion of percutaneous end
August 3, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations.
The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. It uses a patch placed against the artery wall and is secured on the outside of the vessel by an an attached suture connected to t
PLANO, Texas, Jan. 5, 2016 /PRNewswire/ -- Argon Medical Devices, Inc. announced the completed acquisition of three vascular products from Rex Medical, LLC. The OptionELITE™ Retrievable Vena Cava Filter, CLEANER™ Rotational Thrombectomy System, and UltraStream™ Chronic Hemodialysis Catheter are now wholly owned by Argon Medical Devices, Inc. Prior to this transaction, the products were licensed and distributed by Argon through an exclusive agreeme
Armed Poxvirus selectively destroys tumor cells
SAN FRANCISCO and YONGIN, South Korea, January 12, 2009 /PRNewswire/ -- Jennerex,
Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., today announced treatment of the first five patients in a Phase 2 primary liver cancer clinical trial using its targeted and armed poxvirus JX-594. No significant toxicities were reported, and enrollment of patients onto the trial is continuing.